Login
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

meiragtx.com

What Do They Do?

Licenses genetic-medicine rights and provides research, development and manufacturing services to biopharmaceutical partners, while developing gene therapies for eye, salivary-gland and neurological conditions.

How Do They Make Money?

License partners pay for rights to genetic-medicine programs, including upfront and milestone payments; collaborators also pay for research, development and manufacturing services as work is performed.

revenue
SegmentShareRevenue
Service revenue - related party
Recurring
7.9%
License revenue
Licensed

92%

Who Are Their Customers?

Biopharmaceutical collaborators work directly with MeiraGTx on licenses and research, development and manufacturing; Johnson & Johnson also receives gene-therapy supply under a supply agreement.

Do Revenues Turn Into Profits?

No. It lost $114.2M in FY2025.

Operating income, FY2025
−130% of revenue
▲ +35% (Loss) vs FY2024 (−$164.2M, −493%)
Net income, FY2025
−140% of revenue
▲ +23% (Loss) vs FY2024 (−$147.8M, −444%)
Free cash flow, FY2025
−62% of revenue
▲ +54% (Loss) vs FY2024 (−$109.5M, −329%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +1074%
vs $410K in Q3 FY2025
Net income
▼ −1% (Loss)
vs −$50.5M in Q3 FY2025
  • Apr 20, 2026 Hologen collaboration established development and licensing arrangements The agreement covers Parkinson’s and genetic-obesity programs, other central-nervous-system medicines and a delivery device.
  • Apr 15, 2026 MeiraGTx acquired RPGR gene-therapy rights from Janssen The purchase covers the license and related assets for the X-linked retinitis pigmentosa product.

Growing. Revenue grew 2.2x in 4 years, from $37.7M in FY2021 to $81.4M in FY2025, about 21% a year.

Revenue over time
Service revenue - related party License revenue
$100M$50M$0

Who Do They Compete With?

Competes with Spark Therapeutics, Voyager Therapeutics, and Lilly

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support